Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Schuchmann

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
World Journal of Gastroenterology|January 27, 2006
MORT1/FADD is involved in liver regenerationMarcus Schuchmann, Felix Ruckert, Jose F Garcia-Lazaro, et al.
European Journal of Internal Medicine|May 25, 2010
Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD)Tim Zimmermann, Maria Hoppe-Lotichius, Vuk Tripkovic, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 16, 2012
Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIPJörn M Schattenberg, Michael Nagel, Yong Ook Kim, et al.
The American Journal of Gastroenterology|October 16, 2008
Mycophenolate mofetil as second line therapy in autoimmune hepatitis?Elke M Hennes, Ye H Oo, Christoph Schramm, et al.
Cell Death & Disease|June 23, 2017
Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieuYvonne Huber, Nadine Gehrke, Jana Biedenbach, et al.
Hepatology (Baltimore, Md.)|February 21, 2013
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cellsMartin Franz Sprinzl, Florian Reisinger, Andreas Puschnik, et al.
Hepatology (Baltimore, Md.)|January 26, 2010
Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in miceAchim Weber, Regina Boger, Binje Vick, et al.
BMC Cancer|March 24, 2012
Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significanceMichael Heise, Anja Lautem, Johanna Knapstein, et al.
Journal of Clinical Gastroenterology|September 19, 2013
Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC RegistryArndt Weinmann, Sandra Koch, Ina M Niederle, et al.
Journal of Hepatology|May 21, 2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff, Heiner Wedemeyer, Wulf O Boecher, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
World Journal of Gastroenterology|January 27, 2006
MORT1/FADD is involved in liver regenerationMarcus Schuchmann, Felix Ruckert, Jose F Garcia-Lazaro, et al.
European Journal of Internal Medicine|May 25, 2010
Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD)Tim Zimmermann, Maria Hoppe-Lotichius, Vuk Tripkovic, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 16, 2012
Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIPJörn M Schattenberg, Michael Nagel, Yong Ook Kim, et al.
The American Journal of Gastroenterology|October 16, 2008
Mycophenolate mofetil as second line therapy in autoimmune hepatitis?Elke M Hennes, Ye H Oo, Christoph Schramm, et al.
Cell Death & Disease|June 23, 2017
Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieuYvonne Huber, Nadine Gehrke, Jana Biedenbach, et al.
Hepatology (Baltimore, Md.)|February 21, 2013
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cellsMartin Franz Sprinzl, Florian Reisinger, Andreas Puschnik, et al.
Hepatology (Baltimore, Md.)|January 26, 2010
Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in miceAchim Weber, Regina Boger, Binje Vick, et al.
BMC Cancer|March 24, 2012
Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significanceMichael Heise, Anja Lautem, Johanna Knapstein, et al.
Journal of Clinical Gastroenterology|September 19, 2013
Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC RegistryArndt Weinmann, Sandra Koch, Ina M Niederle, et al.
Journal of Hepatology|May 21, 2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff, Heiner Wedemeyer, Wulf O Boecher, et al.
Pageof 9